Albuvirtide
A long-acting HIV fusion inhibitor licensed in China
Albuvirtide is a long-acting peptide that stops HIV-1 from fusing with human cells, the same step targeted by enfuvirtide. Developed in China and given by intravenous infusion, it is licensed only in China, where a phase 3 trial found it non-inferior to standard nucleoside drugs as part of second-line treatment.
Used in human trials: 640 mg (with dolutegravir 50 mg daily), Every 4 weeks, Intravenous bolus (Trial: switch study with dolutegravir) Details ↓
Recommended Dosing
Used in human trials
No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.
Work out syringe units → · New to syringes? · All dosing data ↓ · Dose and vial tracker · Is this vial OK?
What is it?
HIV enters cells by fusing its envelope with the cell membrane. Enfuvirtide, approved in the US in 2003, blocks that step but must be injected twice daily. Albuvirtide was designed as a long-acting fusion inhibitor and, according to a 2024 pharmacokinetic study, is the first developed in China; later studies describe it as licensed only there.
Its pivotal phase 3 trial enrolled antiretroviral-experienced adults. At 48 weeks, 80.4% of those given albuvirtide with lopinavir/ritonavir had HIV RNA below 50 copies/mL, against 66.0% on a nucleoside-based regimen, meeting non-inferiority, with superiority in the per-protocol analysis and similar rates of severe adverse events. An earlier study combining it with lopinavir/ritonavir found a clear dose-response. A pharmacokinetic study of the same combination found that lopinavir/ritonavir barely changed albuvirtide exposure, but albuvirtide lowered lopinavir and ritonavir exposure by roughly a third, which the authors judged may not reduce the regimen's effectiveness.
Newer studies have moved toward simpler dosing. Virologically suppressed adults switched to 640 mg every four weeks with daily dolutegravir all stayed suppressed for 24 weeks, and in post-exposure prophylaxis, albuvirtide regimens were completed far more often than all-oral ones (88.9% against 64.0%).
Smaller Chinese studies have explored it in people whose CD4 counts fail to recover on treatment, where intensive albuvirtide raised CD4 counts by 45 cells/µL against a fall of 5 in controls, and in hospitalised patients and those with opportunistic infections. It is not approved outside China. More recent real-world series report it intensifying treatment in low-level viraemia, adding immune recovery when started with bictegravir in advanced disease, and, with the antibody 3BNC117, suppressing multidrug-resistant HIV in a small trial. Most are single-centre or retrospective.
Mechanism of Action
Albuvirtide is a long-acting HIV fusion inhibitor: a peptide modified with 3-maleimidopropionic acid, designed to last far longer than enfuvirtide.
Fusion blockade
It binds the HIV envelope's fusion machinery and blocks the six-helix bundle that lets the virus enter cells.
Long action
Trough levels stayed far above inhibitory concentrations with four-weekly dosing in switch studies.
Broad activity
In the lab it inhibited HIV-1 subtypes A, B and C and recombinants common in China.
Published Research
Studies of albuvirtide, from their PubMed abstracts.
Phase 3 in treatment-experienced adults
In antiretroviral-experienced adults, 80.4% on albuvirtide plus lopinavir/ritonavir and 66.0% on a nucleoside regimen had HIV RNA below 50 copies/mL at 48 weeks, meeting non-inferiority, with superiority per protocol and similar grade 3-4 adverse events.
Dose-finding with lopinavir/ritonavir
At week 7, HIV RNA fell by 1.9 and 2.2 log10 copies/mL at 160 and 320 mg, and fell below 50 copies/mL in 1 of 9 and 5 of 9 patients, showing a clear dose-efficacy relationship.
Interaction with lopinavir/ritonavir
In 10 people with HIV, adding lopinavir/ritonavir left albuvirtide exposure essentially unchanged (AUC ratio 1.09), but lowered lopinavir exposure (AUC ratio 0.63) and ritonavir exposure (0.62); the authors judged this may not reduce effectiveness.
Poor immune recovery
In 50 people whose CD4 counts had not recovered on treatment, intensive albuvirtide raised CD4 counts by 45 cells/µL at 12 weeks against a fall of 5 in controls, and the difference persisted at 24 weeks.
Advanced HIV with Talaromyces infection
In this small case series of advanced HIV with talaromycosis, CD4 counts rose from a median 14 to 83.5 cells/µL on albuvirtide-based regimens, with no severe drug-related adverse events.
Infusion vs bolus in healthy volunteers
In 30 healthy Chinese adults given a single 320 mg dose, peak concentration came at 0.75 hours after a 45-minute drip and 0.16 hours after a bolus, while elimination half-life, clearance and volume of distribution were similar across methods.
Hospitalised patients, with dolutegravir
In 151 hospitalised people with HIV, 93% with bacterial or fungal infections, albuvirtide plus dolutegravir lowered mean HIV RNA from 4.32 to 2.24 log10 copies/mL after 2 weeks and further at 4 weeks, in both treatment-naive and experienced patients.
Every four weeks with dolutegravir
In 9 virologically suppressed adults, an intravenous bolus every 4 weeks plus daily dolutegravir kept everyone suppressed for 24 weeks, with trough levels about 27 times the inhibitory concentration and CD4 counts up a median 66 cells/µL.
Post-exposure prophylaxis
In a 120-man non-randomised cohort, albuvirtide plus dolutegravir for post-exposure prophylaxis had higher 28-day completion (96.7% against 86.7%) and fewer adverse events than the standard regimen; no one seroconverted.
Switching to every 4 weeks
Virologically suppressed adults switched to albuvirtide 640 mg every 4 weeks plus daily dolutegravir all stayed suppressed for 24 weeks, with no serious adverse events, troughs about 31 times the protein-adjusted IC90 and a rise in CD4 counts.
Post-exposure prophylaxis adherence
In 330 people starting HIV post-exposure prophylaxis, regimens containing albuvirtide had higher 28-day completion (88.9% against 64.0%) and adherence (94.4% against 75.7%) than oral regimens.
Second-line regimen comparison
In 71 patients failing first-line treatment, viral suppression below 50 copies/mL was 82.4% with albuvirtide plus lopinavir/ritonavir against 29.7% with two NRTIs plus lopinavir/ritonavir in a retrospective comparison.
Advanced HIV starting bictegravir
In treatment-naive advanced HIV, adding albuvirtide to bictegravir/emtricitabine/tenofovir alafenamide was associated with more patients reaching the immune-recovery composite (45.5% against 22.6%) and larger CD4 gains, with similar adverse events.
Hospitalised advanced AIDS, real world
In 174 hospitalised people with advanced AIDS given albuvirtide plus dolutegravir or dolutegravir/lamivudine, 79.9% were suppressed at 24 weeks; treatment-related adverse events occurred in 5.2%.
Low-level viraemia
In 27 people with persistent low-level viraemia, albuvirtide intensification brought 85.2% to undetectable by week 28 and raised CD4 counts by about 124 cells/µL, with no serious adverse events.
A modified intensification regimen
A modified albuvirtide intensification added to standard therapy kept trough levels more than 50-fold above the IC90 and lowered mean HIV RNA by about 1 log over 12 weeks, with no related adverse events.
With the antibody 3BNC117 for multidrug resistance
In 16 patients with multidrug-resistant HIV, albuvirtide plus the broadly neutralising antibody 3BNC117 lowered viral load by 2.82 log on average, with 87.5% below 50 copies/mL at the end of treatment.
Interaction with rifampicin
In a phase 1 study, albuvirtide lowered rifampicin's steady-state exposure by about 20%, and the pharmacokinetics of both drugs changed somewhat when given together.
Broad activity in the lab
Albuvirtide blocked HIV-1 envelope-mediated fusion and entry across a panel of 42 pseudoviruses, including subtypes A, B and C and recombinants circulating in China.
Dosing Data
Licensed only in China. The phase 3 trial gave it once weekly; newer studies give 640 mg every 4 weeks with daily dolutegravir.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
Unknown: we hold no label and no published test that says what forms or vial sizes Albuvirtide is sold in. A vial's own label is a seller's claim, not a source.
Mixing a vial: a worked example
No worked example: none of the doses on this page is a fixed amount in mg or mcg injected under the skin or into a muscle (the routes given are: intravenous bolus, not stated in the abstract). There is no home-mixing step to show. The reconstitution calculator does the arithmetic for any vial.
Source: the route and amount of each dose row in Dosing Data below.
Storage before and after mixing
Unknown: no label or published stability study on file says how to store Albuvirtide, before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long Albuvirtide stays intact once mixed.
How it is taken
As it was given in human studies: Intravenous bolus (Every 4 weeks; Trial: switch study with dolutegravir); Not stated in the abstract (Every 4 weeks; Trial: switching suppressed adults).
For injection technique, sites and needle disposal, see the mixing guide.
Source: Used in human trials: the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: not established by a measurement cited on this entry.
How long the doses were given: Trial: switch study with dolutegravir: 24 weeks; Trial: switching suppressed adults: 24 weeks.
When effects appear: unknown; no source on this page gives a time to effect for Albuvirtide. Results reported in the studies are under Published Research.
Source: Used in human trials, the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Grade 3-4 adverse events at similar rates to a nucleoside regimen in the phase 3 trial. Full list and cautions ↓
When to stop or get help: unknown; no label or trial on file sets rules for stopping Albuvirtide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the studies above”).
Interactions
- lopinavir/ritonavir: albuvirtide exposure essentially unchanged (AUC ratio 1.09), but lopinavir (AUC ratio 0.63) and ritonavir (0.62) exposure fell; authors judged effectiveness may not be reduced
Every peptide's record, with its source: the interaction matrix.
Source: human study, PMID 27052428.
Checking what you bought
Unknown: no published independent test of Albuvirtide products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: Not FDA Approved (Not approved by FDA (no Drugs@FDA record found)). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
No US label; it is not approved in the US.
Legal Status
Albuvirtide is licensed in China but not in the US.
Frequently Asked Questions
?How is albuvirtide different from enfuvirtide?
Both block HIV fusion with cells; albuvirtide is long-acting and given by infusion, whereas enfuvirtide is injected under the skin twice a day.
?Is albuvirtide approved in the US?
No. It is licensed only in China.
?How well does it work?
In its phase 3 trial, 80.4% of patients on albuvirtide plus lopinavir/ritonavir had undetectable virus at 48 weeks against 66.0% on a nucleoside regimen.
?Can it be given as a quick injection instead of a drip?
In healthy volunteers, a bolus injection reached peak levels sooner than a 45-minute drip, but half-life, clearance and distribution were similar, suggesting the faster method gives comparable exposure.
?Can albuvirtide be given monthly?
In switch studies, 640 mg every 4 weeks plus daily dolutegravir kept all participants virologically suppressed for 24 weeks, with no serious adverse events.
?Is it used for post-exposure prophylaxis?
In Chinese cohorts, yes: regimens containing albuvirtide had higher 28-day completion and adherence than oral regimens.
References
- [clinical-trial] Su B, et al. "Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study." Chin Med J (Engl), 2020;133(24):2919-2927. PMID: 33252379.
- [clinical-trial] Zhang H, et al. "Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients." AIDS Res Ther, 2016;13:8. PMID: 26865854.
- [pubmed] Yang W, et al. "Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results." Xenobiotica, 2017;47(2):133-143. PMID: 27052428.
- [clinical-trial] Fan L, et al. "Enhanced immune reconstitution with albuvirtide in HIV-infected immunological non-responders." Front Cell Infect Microbiol, 2024;14:1397743. PMID: 38975330.
- [pubmed] Yu X, et al. "Albuvirtide-based regimens for advanced- stage HIV and Talaromyces marneffei co-infection: A longitudinal case series." Int J STD AIDS, 2026;37(8):846-852. PMID: 41947318.
- [pubmed] Qin H, et al. "Comparison of pharmacokinetics and safety of albuvirtide in healthy subjects after intravenous drip and bolus injection." Naunyn Schmiedebergs Arch Pharmacol, 2024;397(2):913-922. PMID: 37535074.
- [pubmed] Liu H, et al. "Tolerability and effectiveness of albuvirtide combined with dolutegravir for hospitalized people living with HIV/AIDS." Medicine (Baltimore), 2023;102(45):e35344. PMID: 37960773.
- [clinical-trial] Fu Y, et al. "Safety, pharmacokinetics, and efficacy of albuvirtide administered by intravenous bolus every 4 weeks in combination with oral dolutegravir in virologically suppressed adults living with HIV: A 24-week study." Int J Infect Dis, 2026;162:108163. PMID: 41429707.
- [pubmed] Liu H, et al. "Safety and efficacy of albuvirtide and dolutegravir for HIV postexposure prophylaxis in men who have sex with men: a prospective non-randomized cohort study." BMC Infect Dis, 2026;26(1). PMID: 41882553.
- [pubmed] Xie X, et al. "Safety and efficacy of switching to 4-weekly albuvirtide plus daily dolutegravir in virologically suppressed HIV-1 adults: a 24-week study." AIDS, 2025;39(7):857-862. PMID: 39874112.
- [pubmed] Nie J, et al. "Tolerability and Adherence of Antiretroviral Regimens Containing Long-Acting Fusion Inhibitor Albuvirtide for HIV Post-Exposure Prophylaxis: A Cohort Study in China." Infect Dis Ther, 2021;10(4):2611-2623. PMID: 34586592.
- [pubmed] Chen L, et al. "Comparing albuvirtide plus ritonavir-boosted lopinavir regimen to two nucleotide reverse transcriptase inhibitors plus ritonavir-boosted lopinavir in HIV-infected individuals who failed initial treatment: a retrospective comparative cohort study." Ann Transl Med, 2022;10(20):1125. PMID: 36388832.
- [pubmed] Zhu Y, et al. "Adjunctive albuvirtide is associated with improved immune recovery in treatment-naive patients with advanced HIV disease receiving bictegravir/emtricitabine/tenofovir alafenamide: a retrospective propensity score-matched cohort study." Front Immunol, 2026;17:1900068. PMID: 42639035.
- [pubmed] Liu H, et al. "Efficacy and Safety of Albuvirtide Plus Dolutegravir or Dolutegravir/Lamivudine in Hospitalized People with Advanced AIDS: A Retrospective Real-World Study." AIDS Res Hum Retroviruses, 2026;42(10-11):279-285. PMID: 42576299.
- [pubmed] Zhang C, et al. "Efficacy and safety of albuvirtide intensification for low-level viremia in people with HIV-1: A retrospective pilot study." Int J Infect Dis, 2026;168:108671. PMID: 41921900.
- [pubmed] Hu C, et al. "Safety and Virological Outcomes of a Modified Albuvirtide Intensification Regimen with Standard ART in People with HIV." Infect Drug Resist, 2026;19:617345. PMID: 42677045.
- [pubmed] Zhou Y, et al. "Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial." BMC Infect Dis, 2026;26(1). PMID: 41896772.
- [pubmed] Zhang L, et al. "Drug-Drug Interaction Between Rifampicin and Albuvirtide: A Phase 1, Randomized, Open-Label Study." J Clin Pharmacol, 2025;65(7):885-894. PMID: 39840531.
- [pubmed] Chong H, et al. "Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor." PLoS One, 2012;7(3):e32599. PMID: 22403678.
Sources & Citations
Studies were read from their PubMed abstracts. Read October 7, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.